A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Trial Profile

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Savolitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Preliminary results (Cut off 27 June 2016) presented at the 2017 Genitourinary Cancers Symposium
    • 14 Feb 2017 Results from this trial will be presented at the 2017 Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO-GU), according to a Chi-Med media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top